Abstract
The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States. The key relationship between these two diseases (knowing that T2DM is a strong risk factor for cardiovascular disease) is insulin resistance and the detrimental effect it has on macrovasculature. Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor? agonists that are beneficial in the treatment of T2DM and have the added benefit of modifying lipid profiles. This review discusses the basic science linking insulin resistance to atherosclerosis and describes the major TZD trials in the recent literature. It also addresses the clinical implications of these studies and media scrutiny surrounding the recent controversial report that TZDs may be linked to an increased risk of myocardial infarction.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Hamman RF, Wing RR, Edelstein SL, et al.: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006, 29:2102–2107.
Semple RK, Chaterjee VK, O’Rahilly S: PPARa and human metabolic disease. J Clin Invest 2006, 116:581–589.
Auboeuf D, Rieusset J, Fajas L, et al.: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 46:1319–1327.
Finck BN: The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 2007, 73:269–277.
Gearing KL, Göttlicher M, Teboul M, et al.: Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A 1993, 90:1440–1444.
Tugwood JD, Issemann I, Anderson RG, et al.: The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992, 2:433–439.
Krogsdam AM, Nielsen CA, Neve S, et al.: Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation. Biochem J 2002, 363(Pt 1):157–165.
Dichtl W, Nilsson L, Goncalves I, et al.: Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 1999, 84:1085–1094.
Ricote M, Li AC, Willson TM, et al.: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79–82.
Marx N, Schönbeck U, Lazar MA, et al.: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83:1097–103.
Takeda K, Ichiki T, Tokunou T, et al.: Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000, 102:1834–1839.
Goetze S, Xi XP, Graf K, et al.: Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 1999, 452:277–282.
Wang CC, Goalstone ML, Draznin B: Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004, 53:2735–2740.
Hsueh WA, Law RE: Insulin signaling in the arterial wall. Am J Cardiol 1999, 84(1A):21J–24J.
Miyazaki Y, He H, Mandarino LJ, et al.: Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003, 52:1943–1950.
Arslanian SA, Lewy V, Danadian K, et al.: Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002, 87:1555–1559.
Bailey CJ, Turner RC: Metformin. N Engl J Med 1996, 334:574–579.
Kim JK, Fillmore JJ, Gavrilova O, et al.: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 2003, 52:1311–1318.
Norris AW, Chen L, Fisher SJ, et al.: Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003, 112:608–618.
Hevener AL, He W, Barak Y, et al.: Muscle-specific PPARg deletion causes insulin resistance. Nat Med 2003, 9:1491–1497.
Sethi S, Eastman AY, Eaton JW: Inhibition of phagocyteendothelium interactions by oxidized fatty acids: a natural anti-inflammatory mechanism? J Lab Clin Med 1996, 128:27–38.
Sethi S, Ziouzenkova O, Ni H, et al.: Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 2002, 100:1340–1346.
Nohé B, Johannes T, Dieterich HJ: Antiinflammatory effects of omega-3 fatty acids vary at different stages of inflammation. Am J Physiol Heart Circ Physiol 2003, 285:H2248–H2249.
Murray AJ, Panagia M, Hauton D, et al.: Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 2005, 54:3496–3502.
Neubauer S, Horn M, Cramer M, et al.: Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190–2196.
Belfort R, Harrison SA, Brown K, et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297–2307.
Schlierf G, Dorow E: Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J Clin Invest 1973, 52:732–740.
Szczepaniak LS, Dobbins RL, Metzger GJ, et al.: Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003, 49(3):417–423.
Bocos C, Göttlicher M, Gearing K, et al.: Fatty acid activation of peroxisome proliferator-activated receptor (PPAR). J Steroid Biochem Mol Biol 1995, 53(1–6):467–473.
Rodríguez VM, Portillo MP, Picó C, et al.: Olive oil feeding up-regulates uncoupling protein genes in rat brown adipose tissue and skeletal muscle. Am J Clin Nutr 2002, 75:213–220.
McGavock JM, Victor RG, Unger RH, et al.: Adiposity of the heart, revisited. Ann Intern Med 2006, 144:517–524.
Collins AR, Meehan WP, Kintscher U, et al.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptordeficient mice. Arterioscler Thromb Vasc Biol 2001, 21:365–371.
Zierath JR, Ryder JW, Doebber T, et al.: Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 1998, 139:5034–5041.
Kim SY, Kim HI, Park SK, et al.: Liver glucokinase can be activated by peroxisome proliferator-activated receptorgamma. Diabetes 2004, 53(Suppl 1):S66–S70.
Delerive P, De Bosscher K, Besnard S, et al.: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048–32054.
de Winther MP, Kanters E, Kraal G, et al.: Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005, 25:904–914.
Calnek DS, Mazzella L, Roser S, et al.: Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003, 23:52–57.
Daynes RA, Jones DC.: Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002, 2:748–759.
Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169:453–459.
Ricote M, Li AC, Willson TM, et al.: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79–82.
Pasceri V, Wu HD, Willerson JT, et al.: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101:235–248.
Chen Z, Ishibashi S, Perrey S, et al.: Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001, 21:372–377.
Nagashima K, Lopez C, Donovan D, et al.: Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005, 115:1323–1332.
Goldberg RB, Kendall DM, Deeg MA, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547–1554.
Ting HJ, Stice JP, Schaff UY, et al.: Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res 2007, 100:381–390.
Nordestgaard BG, Benn M, Schnohr P, et al.: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299–308.
Wilcox R, Bousser MG, Betteridge DJ, et al.: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007, 38:865–873.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096–1105.
Krall RL: Cardiovascular safety of rosiglitazone. Lancet 2007, 369:1995–1996.
Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427–2443.
Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005, 48:1726–1735.
Mazzone T, Meyer PM, Feinstein SB, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572–2581.
Takagi T, Yamamuro A, Tamita K, et al.: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003, 146:E5.
Choi D, Kim SK, Choi SH, et al.: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2654–2660.
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sulistio, M.S., Zion, A., Thukral, N. et al. PPARγ agonists and coronary atherosclerosis. Curr Atheroscler Rep 10, 134–141 (2008). https://doi.org/10.1007/s11883-008-0020-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11883-008-0020-4